- home
- application
- Pharmaceutical
Pharmaceutical
In pharmaceutical production, consistency, purity, and regulatory compliance are non-negotiable.
applications
recent posts

Laminar Co., Ltd. to Exhibit at ACHEMA 2022 in Frankfurt
July 29, 2022


Free Webinar Hosted by Our UK Distributor, Analytik
October 1, 2021
speak to experts
we develop next-generation chemical reactor systems that harness the power of laminar Taylor flow
- +82-31-737-2375
- sales@laminarm.co.kr
APPLICATION OVERVIEW
Continuous, High-Purity Solutions for API and Fine Chemical Manufacturing
Lamina’s LCTR® (Laminar Continuous Taylor Reactor) offers a transformative solution for API synthesis, crystallization, purification, and particle engineering, enabling scalable continuous manufacturing with unmatched control. By minimizing batch-to-batch variation and enabling tighter control over temperature, residence time, and mixing efficiency, LCTR® systems allow pharmaceutical companies to meet GMP standards while optimizing cost and time.
Why LCTR® for Pharma?
- Enables high-purity output through precise control of crystallization and reaction conditions.
- Reduces processing time by integrating reaction, separation, and purification into a continuous flow.
- Delivers consistent results with uniform residence time and stable flow dynamics.
- Scales seamlessly from lab development to GMP-compliant industrial production.
- Minimizes solvent usage and waste, supporting greener pharmaceutical manufacturing.
- Aligns with global regulatory trends toward continuous manufacturing (FDA, EMA).
01. Drowning-out crystallization
- Objective: Time reduction, continuous
SMZ (Sulfameraine)
| CSTR | LCTR | |
| Production Time | 93 hours | 20 min |
02. Polymorphism
- Target : Amorphous → Crystal (cubic)
Enantiomer separation (Deracemization)
- Results: Decreased separation time (150 h → 12 h)
* ee: enantiomer excess value * These research results are excerpted from the work of Professor Woosik Kim of Kyung Hee University.